Clinical trial Recruiting at 2 sites Phase 3 Interventional Ages 18 to 100

Polypill approach to reduce vascular risk after stroke in Ghana

Official title: Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment II Study (SMAART II)

Run by Northern California Institute of Research and Education · NCT05963568 · Data updated 2026-11-12

This study tests whether taking a single daily Polycap polypill (blood-pressure meds, a statin, and aspirin) for two years helps stroke patients in Ghana reduce their risk of future vascular events compared with usual care.

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years to 100 Years
SexAll
Enrollment1000 (estimated)
SponsorNorthern California Institute of Research and Education
Academic / other
Locations4 sites (Parakou and 3 other locations)
StatusRecruiting
StartedApril 1, 2026
Main results expectedJanuary 31, 2029
Study endsFebruary 1, 2029
Registry record updatedJuly 6, 2026
Trial IDNCT05963568 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (18+) who recently had an ischemic stroke (within 2 months) and have at least one risk factor such as hypertension, diabetes, or prior cardiovascular disease.

Probably not a fit

Patients without contraindications to the polypill or those not experiencing a risk reduction may not see benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

SMAART II is a phase 3 trial enrolling adults who recently had an ischemic stroke in several Ghanaian hospitals. The study compares daily Polycap fixed-dose therapy to standard care over 24 months, aiming to lower composite vascular risk. It uses a hybrid design to assess both efficacy and how best to implement polypill use in an under-resourced healthcare setting. Participants must meet criteria such as age over 18, ischemic stroke within 2 months, and at least one cardiovascular risk factor or comorbidity. The trial seeks to inform routine integration and policy adoption if beneficial.

Why it matters

Potential benefit: If successful, patients could experience lower risk of recurrent stroke and other vascular events through a simple, once-daily therapy.

How similar studies have gone: Prior similar polypill approaches have shown promise, but results vary by setting; SMAART II explores real-world implementation in Ghana.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Above the age of 18 years; male or female
* Ischemic stroke diagnosis no greater than two months before enrollment. Ischemic strokes including� lacunar, large-vessel atherosclerotic, cardio-embolic subtypes are eligible
* Subjects with stroke may present with at least one of the following additional conditions:

Documented diabetes mellitus or previous treatment with oral hypoglycemic or insulin; documented hypertension \>140/90mmHg or previous treatment with antihypertensive medications; Mild to moderate renal dysfunction (eGFR 60-30ml/min/1.73m2); Prior myocardial infarction

* Legally competent to sign informed consent.

Exclusion Criteria:

* Unable to sign informed consent
* Contraindications to any of the components of the polypill
* Hemorrhagic stroke
* Severe cognitive impairment/dementia or severe global disability limiting the capacity of self-care
* Severe congestive cardiac failure (NYHA III-IV)
* Severe renal disease, eGFR \<30ml/min/1.73m2), renal dialysis; awaiting renal transplant or transplant recipient
* Cancer diagnosis or treatment in past 2 years
* Need for oral anticoagulation at the time of randomization or planned in the future months;
* Significant arrhythmias (including unresolved ventricular arrhythmias or atrial fibrillation)
* Nursing/pregnant mothers
* Do not agree to the filing, forwarding and use of his/her pseudonymized data.

Where it's running

  • University Teaching Hospital of Parakou
    Parakou, Benin
    Recruiting
  • University of Ilorin Teaching Hospital
    Ilorin, Nigeria
    Recruiting
  • Kwame Nkrumah Institute of Science & Technology
    Kumasi, Ghana
    Active not recruiting
  • Aga Khan Hospital
    Dar es Salaam, Tanzania
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.